Bausch + Lomb to Highlight Product Data at European Dry Eye Congress
- Scientific presentations will evaluate multiple products from the Artelac® portfolio in dry eye disease, including Artelac Complete and Artelac Ultra 4S
- Findings from a national survey in China reveal patient and practitioner satisfaction with Artelac Nighttime Gel in dry eye disease
- In-depth analyses explore the role of B-vitamins in ocular surface health and how ectoine can help in the treatment of dry eye disease
VAUGHAN, Ontario, June 15, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced six poster presentations at the European Dry Eye Congress in Milan, Italy, June 18-20, 2026.
Two presentations will highlight real-world data examining clinical outcomes, utilization patterns and practitioner satisfaction with Artelac Complete Preservative Free Lubricating Eye Drops and Artelac Ultra 4S Lubricating Drops. Additionally, the company will present a literary review on the role of B-vitamins in ocular surface health, clinical insights exploring the role of ectoine in dry eye disease and findings from a national survey in China on real-world use of Artelac Nighttime Gel.
The company is a diamond sponsor of this year’s congress and will host educational events focused on these and other Bausch + Lomb products.
Below is a complete list of Bausch + Lomb scientific presentations and events.
Poster Presentations
- “Exploring the Role of Ectoine in the Treatment of Dry Eye Disease.” Uçakhan-Gündüz O.
- “Retrospective Real-World Evidence Study: Clinical Outcomes, Utilisation Patterns, and Eye Care Practitioner Satisfaction with Artelac Ultra 4S (RecuDrop) Lubricating Drops in Patients with Dry Eye Disease.” Merayo-Lloves J.
- “Clinical Outcomes, Utilisation Patterns, and Eye Care Practitioner Satisfaction with Artelac Complete Dry Eye Lubricating Drops: A Retrospective Real-World Evidence Study.” Woźniak P.
- “A Drop in the Right Direction: Refining Artificial Tear Formulations in the Context of TFOS DEWS III.” Labetoulle M.
- “B-YOND Antioxidants: A Look at B-Vitamins from Both Sides of the Ocular Surface.” Benítez del Castillo J.
- “Real-World Use of Carbomer Gel (Liposic) in Dry Eye Disease in China: Results from a National Survey.” Chong K.
Symposium
Refining artificial tears to address the complexity of tear film dysfunction
- Friday, June 19 at 12:00–12:45 CEST
- Presenter: Wassim Altroudi, MD; Leonie Menghesha MD, FEBO; Piotr Wozniak, MD, PhD; Omür Uçakhan-Gündüz, MD
- During this symposium, leading experts will explore the dry eye landscape, how the condition impacts sufferers, innovations in artificial tear formulations and how ectoine can play a key role in osmoprotection. In addition to presentations, the session will include a panel discussion.
Industry Innovation Session
Transforming Eye Care Innovation Together
- Saturday, June 20 at 11:35–11:40 CEST
- Presenter: Mohamed Yassine, MD, vice president, Global Medical & Scientific Affairs, Bausch + Lomb
*Artelac eye drops are not available in the United States.
###
About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
©2026 Bausch + Lomb.
MTB.0236.USA.26
Media Contact:
Caryn Marshall
[email protected]
(908) 493-1381